Charlotte Andersson has substantial experience of quality assurance from the medtech industry, IVD business (In vitro Diagnostics), and the pharmaceutical and biotech area. She has held different positions within quality management, including ISO 13485, ISO 17025, GMP (Good Manufacturing Practice), GCP (Good Clinical Practice) and GLP (Good Laboratory Practice). At BioInvent, she was the Senior Quality Assurance Advisor and has also held different positions within the quality field at companies like Wieslab, EuroDiagnostica, Orifice Medical och NovoZymes Biopharma Sweden. Charlotte Andersson replaces Åsa Anderlind, who leaves Enzymatica for other assignments. Charlotte Andersson will be a member of Enzymatica’s management team and assumes her position on September 1st 2021.
Stefan Olsson has a long background from the communication industry including agencies like Prime Weber Shandwick and Sund Kommunikation, and has also worked as a management consultant at KPMG. For the last six years, he has worked as an independent communication advisor to management teams and boards of directors of private and listed companies as well as public organizations. In parallel to being Communication Manager at Enzymatica, he will continue as an advisor to other clients. Stefan Olsson assumes his position on July 1st 2021 and will be a co-opted member of the management team. He succeeds Carl-Johan Wachtmeister, who will retire.
“Charlotte and Stefan are two new colleagues with great experience and competence. They will make an excellent contribution to Enzymatica’s continued international expansion,” says Claus Egstrand, Chief Operating Officer.
For more information, please contact:
Claus Egstrand, Chief Operating Officer Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: firstname.lastname@example.org
Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: email@example.com
Stefan Olsson, firstname.lastname@example.org, tel +46 708 55 11 85
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily
conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica’s certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: email@example.com